Schiffon Wong Strategic Advisory

Schiffon Wong Strategic Advisory is a Burlington consulting practice offering senior counsel to biopharma teams on evidence strategy, value and market access. The work centers on making evidence connect with payers: building integrated evidence plans, translating data into value communication grounded in U.S. and EU reimbursement strategy, and preparing companies for EU health technology assessment and Joint Clinical Assessment submissions. A second strand, The Discernment Practice, offers confidential coaching for leaders at consequential career moments.

Schiffon Wong brings two decades in global value strategy, health economics, outcomes research and patient-focused drug development. The career began in clinical research, moved to management consulting at Deloitte, then to leadership roles at Bristol Myers Squibb and EMD Serono, most recently as VP and Head of Neurology and Immunology, Global Value Demonstration. Wong started the practice after seeing that emerging biotechs often lack senior cross-functional evidence leadership and that leaders rarely have a confidential thinking partner.

What to Know

• Engagements include fractional embedded advisory, time-bound projects such as HTA readiness reviews, retainer coaching, and speaking or workshop facilitation.
• Current client work focuses on neurology, immunology and rare disease.
• Wong’s real-world evidence work won a Scrip Award, and a patient-focused program earned a Brandon Hall Gold Award.
• Wong contributed to a PhRMA real-world evidence workgroup for five years starting at its 2017 inception.
• The record includes more than one hundred publications and invited presentations.